Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
A Phase II Multicenter Trial to Assess the Safety and Efficacy of Campath-1H and Tacrolimus Followed By Immunosuppression Withdrawal in Liver Transplantation (ITN024ST)
National Institute of Allergy and Infectious Diseases (NIAID)